- Home
- NIVF vs CPHI Comparison
NIVF vs CPHI Comparison
Compare NIVF & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- CPHI
- Stock Information
- Founded
- NIVF 2011
- CPHI N/A
- Country
- NIVF Hong Kong
- CPHI China
- Employees
- NIVF N/A
- CPHI N/A
- Industry
- NIVF
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- CPHI Health Care
- Exchange
- NIVF NYSE
- CPHI Nasdaq
- Market Cap
- NIVF 5.0M
- CPHI 4.0M
- IPO Year
- NIVF N/A
- CPHI N/A
- Fundamental
- Price
- NIVF $0.28
- CPHI $0.19
- Analyst Decision
- NIVF
- CPHI
- Analyst Count
- NIVF 0
- CPHI 0
- Target Price
- NIVF N/A
- CPHI N/A
- AVG Volume (30 Days)
- NIVF 5.3M
- CPHI 1.8M
- Earning Date
- NIVF 02-16-2025
- CPHI 11-13-2024
- Dividend Yield
- NIVF N/A
- CPHI N/A
- EPS Growth
- NIVF N/A
- CPHI N/A
- EPS
- NIVF N/A
- CPHI N/A
- Revenue
- NIVF $5,679,218.00
- CPHI $5,544,620.00
- Revenue This Year
- NIVF N/A
- CPHI N/A
- Revenue Next Year
- NIVF N/A
- CPHI N/A
- P/E Ratio
- NIVF N/A
- CPHI N/A
- Revenue Growth
- NIVF N/A
- CPHI N/A
- 52 Week Low
- NIVF $0.24
- CPHI $0.13
- 52 Week High
- NIVF $17.24
- CPHI $0.60
- Technical
- Relative Strength Index (RSI)
- NIVF 36.38
- CPHI 46.10
- Support Level
- NIVF $0.29
- CPHI $0.19
- Resistance Level
- NIVF $0.38
- CPHI $0.24
- Average True Range (ATR)
- NIVF 0.05
- CPHI 0.03
- MACD
- NIVF -0.01
- CPHI -0.00
- Stochastic Oscillator
- NIVF 1.89
- CPHI 4.93
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.